Alto Neuroscience, Inc.: Buy Rating Affirmed on Strong Financial Outlook and Promising Clinical Trials

Analyst Justin Walsh of JonesTrading reiterated a Buy rating on Alto Neuroscience, Inc. (ANRO – Research Report), retaining the price target of $18.00.

Justin Walsh has given his Buy rating due to a combination of factors surrounding Alto Neuroscience, Inc.’s financial and clinical outlook. The company’s recent earnings announcement confirmed that its cash reserves are projected to sustain operations through 2028, providing a stable financial foundation. This financial security supports the company’s ongoing and diverse clinical trials, which are central to its precision medicine approach.
Furthermore, Alto Neuroscience is advancing several promising clinical trials, including the Phase II trial of ALTO-203 for Major Depressive Disorder, which has completed enrollment and is expected to deliver topline data in the second quarter of 2025. The company’s robust pipeline, including trials for cognitive impairment associated with schizophrenia and bipolar depression, is not fully valued by the market, according to Walsh. The upcoming data readouts and presentations at key conferences are anticipated to validate the company’s innovative strategies, reinforcing the Buy rating with an $18 price target.